Compare DJCO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DJCO | EVO |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 821.2M |
| IPO Year | 1995 | N/A |
| Metric | DJCO | EVO |
|---|---|---|
| Price | $484.32 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 89.6K | ★ 111.6K |
| Earning Date | 02-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $348.63 | $2.31 |
| 52 Week High | $674.75 | $4.80 |
| Indicator | DJCO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 30.07 |
| Support Level | $481.78 | N/A |
| Resistance Level | $495.51 | $3.78 |
| Average True Range (ATR) | 33.92 | 0.09 |
| MACD | -2.38 | -0.05 |
| Stochastic Oscillator | 25.46 | 14.38 |
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.